Currently, the cell therapy industry has no viable solution to meet the upcoming substantial rise in manufacturing demand.


Advisory Board

Nicoletta Loggia, Ph.D.
Chief Technical Officer at Orchard Therapeutics

Read More

Fabio Fachin, Ph.D.
Head of Cell Therapy process Development and Automation at Takeda

Read More

Investment Partners


8.75

million EUR venture capital raised

2.9

million EUR public grants

45

billion EUR market size

Source

Investments

Nina Capital
Seed/Seed+ Funding

IST Cube
Seed/Seed+ Funding

Axilium Holding
Seed/Seed+ Funding

HCVC
Seed+ Funding

tecnet equity
Seed+ Funding


Grants